LQDA vs. OCUL, ARQT, CNTA, OPK, ETNB, BCYC, IMNM, TYRA, ABVX, and SPRY Should you be buying Liquidia stock or one of its competitors? The main competitors of Liquidia include Ocular Therapeutix (OCUL), Arcutis Biotherapeutics (ARQT), Centessa Pharmaceuticals (CNTA), OPKO Health (OPK), 89bio (ETNB), Bicycle Therapeutics (BCYC), Immunome (IMNM), Tyra Biosciences (TYRA), ABIVAX Société Anonyme (ABVX), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical preparations" industry.
Ocular Therapeutix (NASDAQ:OCUL ) and Liquidia (NASDAQ:LQDA ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and community ranking.
Liquidia has lower revenue, but higher earnings than Ocular Therapeutix. Liquidia is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.
Ocular Therapeutix has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500.
Ocular Therapeutix received 241 more outperform votes than Liquidia when rated by MarketBeat users. Likewise, 69.72% of users gave Ocular Therapeutix an outperform vote while only 66.55% of users gave Liquidia an outperform vote.
Ocular Therapeutix presently has a consensus price target of $15.17, indicating a potential upside of 142.67%. Liquidia has a consensus price target of $21.00, indicating a potential upside of 58.97%. Given Liquidia's stronger consensus rating and higher probable upside, analysts clearly believe Ocular Therapeutix is more favorable than Liquidia.
In the previous week, Liquidia had 17 more articles in the media than Ocular Therapeutix. MarketBeat recorded 21 mentions for Liquidia and 4 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of -0.04 beat Liquidia's score of -0.22 indicating that Liquidia is being referred to more favorably in the news media.
59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 5.5% of Ocular Therapeutix shares are owned by insiders. Comparatively, 31.6% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Ocular Therapeutix has a net margin of -192.61% compared to Ocular Therapeutix's net margin of -674.42%. Liquidia's return on equity of -76.64% beat Ocular Therapeutix's return on equity.
Summary Ocular Therapeutix beats Liquidia on 12 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding LQDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Liquidia Competitors List
Related Companies and Tools
